While the long-term cognitive effects of TTR knockdown remain uncertain, there is currently no conclusive evidence demonstrating harm in patients with ATTRv polyneuropathy receiving TTR knockdown therapy over the last 10 years. The gene discussed is TTR; the disease is polyneuropathy.